Funding for this research was provided by:
National Heart, Lung, and Blood Institute (HL125218, HL105333, HL060056)
National Institute of General Medical Sciences (GM120609)
British Heart Foundation (FS/13/48/30453, RG/08/006/25302, RG/13/4/30107)
Received: 18 June 2020
Accepted: 19 April 2021
First Online: 10 May 2021
Change Date: 23 July 2021
Change Type: Update
Change Details: In the original publication, the there was a wrong tag in the name of Anton Vonk Noordegraaf.
Change Date: 22 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/S13073-021-00915-W
: This study was approved by the Institutional Review Boards (IRBs) of the Cincinnati Children’s Hospital Medical Center, the East of England Cambridge South national research ethics committee, Columbia University Irving Medical Center as well as the individual IRBs at each of the Enrolling Centers’ institutions. All patients have signed consent forms which are on file at the individual Enrolling Centers. No protected health information (PHI) on any patients enrolled in the PAH Biobank, UK NIHR BioResource, or CUIMC has been forwarded to the data analyzing group. Only the individual Enrolling Centers have the ability to re-contact any of the patients enrolled in the study. All research using these patient samples conformed to the principles of the Helsinki Declaration.
: Written informed consent for publication was obtained from the patients/participants/legal guardians for minors at enrollment.
: CG-J and the Regeneron Genetic Center collaborators are full-time employees of the Regeneron Genetics Center from Regeneron Pharmaceuticals Inc. and receive stock options as part of compensation. Johannes Karten is the full owner of 42Genetics BV. The remaining authors declare that they have no competing interests.